In the past week, SGMT stock has gone down by -1.26%, with a monthly decline of -25.05% and a quarterly plunge of -72.04%. The volatility ratio for the week is 5.97%, and the volatility levels for the last 30 days are 8.18% for Sagimet Biosciences Inc The simple moving average for the past 20 days is -19.08% for SGMT’s stock, with a -50.28% simple moving average for the past 200 days.
Is It Worth Investing in Sagimet Biosciences Inc (NASDAQ: SGMT) Right Now?
There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SGMT is 17.22M and currently, short sellers hold a 12.01% ratio of that float. The average trading volume of SGMT on April 26, 2024 was 1.17M shares.
SGMT) stock’s latest price update
The stock price of Sagimet Biosciences Inc (NASDAQ: SGMT) has dropped by -6.00 compared to previous close of 4.17. Despite this, the company has seen a fall of -1.26% in its stock price over the last five trading days. GlobeNewsWire reported 2024-02-29 that SAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences.
Analysts’ Opinion of SGMT
Many brokerage firms have already submitted their reports for SGMT stocks, with Leerink Partners repeating the rating for SGMT by listing it as a “Outperform.” The predicted price for SGMT in the upcoming period, according to Leerink Partners is $26 based on the research report published on March 25, 2024 of the current year 2024.
Piper Sandler gave a rating of “Overweight” to SGMT, setting the target price at $67 in the report published on August 08th of the previous year.
SGMT Trading at -29.02% from the 50-Day Moving Average
After a stumble in the market that brought SGMT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.07% of loss for the given period.
Volatility was left at 8.18%, however, over the last 30 days, the volatility rate increased by 5.97%, as shares sank -31.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -47.17% lower at present.
During the last 5 trading sessions, SGMT fell by -1.26%, in comparison to the 20-day moving average, which settled at $4.75. In addition, Sagimet Biosciences Inc saw -27.68% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SGMT starting from Happel David, who purchase 12,100 shares at the price of $5.27 back on Mar 26 ’24. After this action, Happel David now owns 639,200 shares of Sagimet Biosciences Inc, valued at $63,731 using the latest closing price.
Happel David, the President & CEO of Sagimet Biosciences Inc, purchase 1,600 shares at $4.10 during a trade that took place back on Dec 07 ’23, which means that Happel David is holding 627,100 shares at $6,560 based on the most recent closing price.
Stock Fundamentals for SGMT
Current profitability levels for the company are sitting at:
- -15.37 for the present operating margin
- 1.0 for the gross margin
The net margin for Sagimet Biosciences Inc stands at -13.94. The total capital return value is set at -0.34.
Based on Sagimet Biosciences Inc (SGMT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -365.63.
Currently, EBITDA for the company is -30.74 million with net debt to EBITDA at 2.44. When we switch over and look at the enterprise to sales, we see a ratio of 25.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.04.
Conclusion
In conclusion, Sagimet Biosciences Inc (SGMT) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
